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Abstract
Objective. The clinical course of SSc depends on subtype, organ involvement and age. Few data are
reported on patients suffering from late-onset SSc.
Methods. We analysed data from 8554 patients prospectively followed in the EULAR Scleroderma Trials
and Research (EUSTAR) group database. Late-onset SSc was defined as onset of non-RP disease
features at or beyond 75 years of age. Disease characteristics, clinical features, disease course and
mortality were evaluated.
Results. A total of 123 patients with SSc onset at or beyond 75 years of age were identified. Compared
with patients <75 years they had more frequently limited than diffuse SSc and a higher prevalence of
anti-centromere autoantibodies. Fewer old patients had digital ulcers. The modified Rodnan’s skin score,
the prevalence of lung fibrosis and renal crisis did not differ significantly between groups. Pulmonary
hypertension (PH) measured by echocardiography was more prevalent in the late-onset group, as well
as arterial hypertension and diastolic dysfunction. Late-onset SSc remained a positive predictor for PH in
multivariate analyses. No significant difference of the two groups in skin score or diffusion capacity was
observed during follow-up. Mortality due to SSc was higher in the late-onset group, but the survival time
from diagnosis was longer compared with the younger patients.
Conclusion. Late-onset SSc shows a distinct clinical presentation and outcome. Patients with late-onset
SSc suffer more frequently from the limited subtype and PH, but fewer patients have digital ulcers. PH
may in part be determined by underlying cardiovascular disease.
Key words: Systemic sclerosis, Scleroderma, Late onset, EULAR Scleroderma Trials and Research, Geriatric,
Elderly.
Introduction
SSc is a heterogeneous CTD. Whereas vasculopathy in
the form of digital ulcers or pulmonary hypertension (PH)
is the leading clinical feature in the limited form, diffuse
SSc is associated with progressive fibrosis of skin and
inner organs. The clinical presentation also depends on
age. Patients with juvenile-onset SSc have less skin
involvement and lower mortality but suffer more frequently
from overlap syndromes, notably with skeletal muscle
involvement [1]. In contrast, patients with onset of RP
above the mean age suffer more frequently from digital
ulcers, lung fibrosis, PH and diastolic heart failure [2].
The mean age at onset of first non-RP in the EULAR
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Scleroderma Trials and Research (EUSTAR) database was
reported as 44.8 years for diffuse SSc and 47.9 years for
limited SSc [2]. In a North American SSc cohort study,
white patients had an older age at diagnosis (55.5 years)
compared with black patients (43.8 years) [3]. Among
white patients, the peak incidence was between 65 and
74 years in women and >75 years in men [3]. The
incidence of SSc >75 years is around 20 cases per million
per year, which is 2–4% of all SSc cases [3].
Data indicate that a late age at onset of SSc is asso-
ciated with more aggressive disease [4]. In fact, the risk of
death increases by 5% for each 1-year increase in age at
diagnosis [3]. The number of patients >75 years at diag-
nosis in previous studies, however, is low and naturally
occurring comorbidity in the elderly certainly influences
survival analysis. Only small SSc cohorts or case series
have focused on late-onset SSc. Whereas some cases
presented with a more severe disease course compared
with patients <60 years, a more benign course, especially
concerning skin involvement, has been reported by others
[5–7]. Despite more severe lung involvement and a
delayed diagnosis in the late-onset group, the disease
remained stable in patients >75 years old [7]. In this
study, we describe disease characteristics, progression
and mortality of late-onset SSc in a larger patient cohort
by analysing the large collection of the EUSTAR database.
Patients and methods
Data sample
We reviewed the minimal essential data set of the EUSTAR
database. The recruitment, structure and content of the
database have been described previously [2]. For SSc
classification, American College of Rheumatology (ACR)
criteria and clinical subsets were defined according to
LeRoy et al. [8]. All participating centres have obtained
ethics committee approval and enter data for all consecu-
tively consenting patients.
Definitions
Late-onset SSc was defined as age 575 years at onset
of first non-RP. This age cut-off has been chosen as
representative of geriatric patients and in accordance
with previous studies [7]. First onset of non-RP was
chosen to assess specifically the first occurrence of
manifest organ involvement.
Data analysis
Patients were dichotomized according to age (<75 or575
years) and data analysed cross-sectionally at study entry.
We analysed follow-up and survival data in all patients with
51 follow-up visits. Both ACR criteria positive and nega-
tive patients were included in the main data set in order to
keep atypical or early SSc cases in the analysis. As a sen-
sitivity analysis, we repeated our analysis limited to the
subset patients with positive ACR criteria only.
Dyspnoea was defined as New York Heart Association
(NYHA) Grade 3 or 4, arterial hypertension as blood pres-
sure >140 mmHg systolic or >90 mmHg diastolic.
Pulmonary fibrosis was diagnosed by CT. Lung restriction
was defined as vital capacity <80%. PH (defined as
systolic pulmonary artery pressure >40 mmHg), diastolic
dysfunction and reduced left ventricular ejection fraction
(LVEF) were diagnosed according to echocardiographic
results reported by the cardiologist. Patients without
tricuspid regurgitation were considered as not having
PH. For disease course analysis, endpoints were defined
as relative diffusing capacity for carbon monoxide (DLCO)
decline of 525% from baseline or modified Rodnan skin
score (mRSS) decline of 53 points, which corresponded
to 25% of the median baseline mRSS in the cohort.
Statistical analysis
Discrete variables are expressed as counts and continuous
variables as medians and interquartile ranges (IQRs).
Two-group comparison was performed with Wilcoxon–
Mann–Whitney tests and a Kruskal–Wallis one-way
analysis of variance was used for multiple-group compari-
sons. Associations of late-onset SSc and other factors with
PH were calculated in logistic regression models. We used
unadjusted and multivariate models adjusted for confoun-
ders and report odds ratios (ORs). Effect modification of
late-onset SSc for the association of diastolic dysfunction
and PH was tested by including an interaction term into the
multivariate regression model. Since the frequency of
missing data was low (<2–5% per variable and <10% for
the multivariate model), we only present a complete case
analysis and did not perform imputation of missing data. All
testing was two-tailed and P< 0.05 was considered stat-
istically significant. All calculations were performed using
Stata 11.0 (Stata Corp., College Station, TX, USA).
Results
Basic description
At the time of data censoring (1 June 2009), 8554 patients
were included in the EUSTAR database. One hundred and
twenty-three patients with a late onset of non-RP at an
age of575 years were identified. Of these, 74.3% fulfilled
the ACR criteria for SSc, whereas ACR criteria were
fulfilled in 84.4% of the patients <75 years (P= 0.002;
Table 1). The median disease duration both of RP
[4.4 (IQR 2–14) vs 10.1 (IQR 4–20) months; P4 0.01]
and non-RP [2.1 (IQR 0.8–3.0) vs 6.8 (IQR 2.8–14.3)
months; P4 0.01] at diagnosis was lower in the late-onset
group. The median disease duration of non-RP symptoms
at study inclusion was also lower in the late-onset group
[30 (IQR 15–48) vs 75 (IQR 36–144) months; P= 0.01].
Significantly more patients in the 575 years group had
limited SSc (74.1 vs 58.2%: P= 0.001), whereas 17.8 vs
32.5% suffered from diffuse disease (P= 0.001). The
late-onset group had a higher proportion of positive anti-
centromere autoantibodies (54.2 vs 33.4%; P< 0.001).
Anti-Scl70 autoantibodies were more prevalent in the
younger group (32.3 vs 23.0%; P= 0.034). ANA positivity
was similar in both groups (94.2 vs 92.1%; P= 0.4).
Significant differences for the same covariates were also
found in the subsets of ACR criteria-positive patients.
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Clinical features
The median mRSS was similar in both age strata (7 vs 7;
P= 0.57; Table 2). The late-onset group had significantly
less digital ulceration (22.1 vs 30.1%; P= 0.03). Patients
with late-onset SSc had higher rates of arterial hyperten-
sion (40.6 vs 20.2%; P< 0.001), abnormal diastolic func-
tion (29 vs 16.1%; P< 0.001) and conduction blocks (21.8
vs 9.7%; P< 0.001). PH was more prevalent in the
late-onset group (35 vs 20%; P< 0.001), whereas there
was no difference in median DLCO between the groups
(45 vs 53%; P= 0.3); the late-onset group did not suffer
more frequently from dyspnoea (40.9 vs 34.3%; P= 0.13).
Similar results and statistical significant differences were
also found in the subset of ACR criteria-positive patients,
except for creatine kinase (CK) elevation, which was simi-
lar in both groups.
To investigate whether late-onset SSc was an
independent risk factor for PH, we calculated logistic
regression analysis (supplementary data are available
at Rheumatology Online). Late-onset SSc was a signifi-
cant predictor for PH with an unadjusted OR of 2.1 (95%
CI 1.5, 3.1). In addition, we found reduced LVEF
[OR 4.78 (95% CI 3.90, 5.86)], abnormal diastolic func-
tion [OR 3.4 (95% CI 3.0, 3.8)], lung fibrosis
[OR 2.7 (95% CI 2.5, 3.1)], conduction block [OR 2.64
(95% CI 2.2, 3.0)] and arterial hypertension [OR 1.82
(95% CI 1.55, 2.14)] to be significant univariate predict-
ors for PH. All those factors remained independent pre-
dictors for PH in multivariate logistic regression analysis.
We found no evidence for effect modification of
late-onset SSc (P of interaction term = 0.2), indicating
that diastolic dysfunction is a risk factor for PH in all
age groups.
TABLE 1 Demographic features at inclusion according to SSc onset by age at first non-RP disease
feature
Disease characteristics Age <75 years Age 575 years P-value
Total number of patients 8431 123
Demographic characteristics
Average age at inclusion, median (IQR) 55 (45.6–64.8) 79.6 (78.2–81.7) <0.0001**
Sex: female, % 86.4 89.3 0.36
Clinical characteristics
Clinical subtype, %
Limited 58.2 74.1 0.001**
Diffuse 32.5 17.8 0.001**
Other 9.1 8 0.67
Disease history
Age at onset of RP, years (IQR) 41 (28–52) 75 (64–78) <0.01
Age at onset of non-RP, years (IQR) 45 (33–56) 78 (76–80) <0.01*
Disease duration of non-RP at diagnosis, months (IQR) 6.8 (2.8–14.3) 2.1 (0.8–3.0) <0.01
Duration of RP at diagnosis, months (IQR) 10.1 (4.4–20.4) 4.4 (2.2–14.5) <0.01
ARC criteria fulfilled 84.4 74.3 0.002*
Autoantibody status, %
Anti-centromere 34.4 54.2 <0.001**
Anti-Scl-70 32.3 23 0.034*
ANA 92.1 94.2 0.4
*Significant; **highly significant.
TABLE 2 Prevalence of clinical features in patients aged
575 vs <75 years
Parameter
Age
<75 years
Age
575 years P-value
MRSS, median (IQR) 7 (3–14) 7 (3–12) 0.57
Synovitis, % 15.8 15.5 0.94
Joint contracture, % 30.1 26.4 0.38
Digital ulcer, % 31.3 22.1 0.03*
Tendon friction rubs, % 10.5 10 0.84
Muscle weakness, % 25.7 21.4 0.28
Muscle atrophy, % 12.8 10.6 0.46
Proteinuria, % 5.8 6.7 0.68
RP, % 95.2 92.6 0.19
Conduction block, % 9.7 21.8 <0.001**
Diastolic function
abnormal, %
16.1 29.6 <0.001**
Diastolic failure, % 5.8 6.7 0.68
PH (echocardiographic), % 20 35 <0.001**
Lung restrictive defect, % 30.7 29.8 0.83
Lung fibrosis, % 36.4 30.1 0.16
Oesophageal
symptoms, %
67.0 59.8 0.09
Intestinal symptoms, % 23.2 26.2 0.77
Renal crisis, % 2.2 0.82 0.29
Dyspnoea, % 34.3 40.9 0.127
Palpitation, % 23.8 21.3 0.50
CK elevation, % 8.2 3.3 0.05*
Arterial hypertension, % 20.2 40.6 <0.001**
Elevated acute phase
reaction, %
29.9 44.5 0.001**
DLCO (% of normal),
median (IQR)
53 (76) 45 (73) 0.30
Reduced left ventricular
function, %
5.2 6.3 0.6
*Significant; **highly significant.
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Disease course
All patients with 51 follow-ups were analysed with
respect to the course of DLCO and mRSS. Severe
and moderate impairment of DLCO (defined as a DLCO
<50 and <65%) were found in 20 and 22% of late-onset
patients, compared with 20 and 27% of control patients.
During the follow-up, 17% of late onset and 11% of
control patients had a decline of at least 25% from
baseline DLCO (P= 0.38). Late-onset patients had lower
median mRSS at study inclusion [4 (IQR 3, 7) vs 7 (IQR
4, 13); P= 0.002], which was also confirmed in multivariate
analysis adjusted for disease duration (P= 0.02). The de-
cline of 53 points in mRSS was also similar in both
groups (28% in late-onset patients vs 34% of control
patients; P= 0.4).
Overall and disease-specific mortality
The overall mortality in the 4081 patients with available
follow-up information was 6.9% (22% in the late-onset
group and 6.7% in the early-onset group; P< 0.001).
Overall, 178 (63%) deaths were attributed to SSc. The
SSc-specific mortality rate was 12.2% in late-onset pa-
tients with a median survival time of 49 months (IQR 22,
92 months) and significantly lower in early-onset patients
(4.3%; P= 0.01), but with a shorter median survival of
41 months (IQR 22, 73 months).
Discussion
This study aimed to characterize clinical features, disease
progression and mortality in late-onset SSc. Unlike that
reported in previous studies, SSc in the late-onset group
was diagnosed earlier then in the control group, which
might be due to a higher frequency of medical consult-
ation or less extensive and invasive diagnostic investiga-
tion in this subgroup [7]. Patients with a late onset suffered
more frequently from limited SSc and had significantly
higher rates of anti-centromere autoantibodies. Despite
the higher prevalence of limited disease, they had fewer
digital ulcers. This suggests a milder disease course in
late-onset SSc patients, but might be biased by a shift
of patients with mild disease into the late-onset group
and the shorter disease duration at study inclusion, re-
spectively. Conversely, PH was more prevalent in
late-onset SSc. However, diastolic dysfunction, arterial
hypertension and conduction blocks, which were also
more prevalent in the late-onset group, can lead to left
ventricular hypertrophy, and thus result non-specifically
in PH [9]. Unfortunately, right heart catheterization was
performed in none of the late-onset patients. The data
set in the present form did not allow us to determine
whether the higher frequency of diastolic dysfunction
and conduction blocks in the late-onset group was
caused by left-ventricle hypertrophy or cardiac fibrosis
due to SSc. Also, false-negative results from echocardi-
ography due to the absence of detectable tricuspid regur-
gitation jet cannot be excluded, although there are no data
to suggest that this would affect elderly SSc patients more
than younger patients. The course of both ILD and skin
involvement remained stable in the majority of both
groups. This is in line with previous reports of a stable
course of signs in elderly SSc, but low mRSS values es-
pecially found in limited SSc are relatively unsensitive and
therefore only of limited value as a marker for disease
progression [7].
ACR criteria were fulfilled in fewer patients in the
late-onset group. This might indicate that, apart from an
earlier study inclusion, older SSc patients suffer from a
more atypical disease course, possibly influenced by
co-medication or comorbidities, such as atherosclerosis.
Studies in patients with late-onset SLE have shown similar
results where they more frequently had RP, arterial hyper-
tension, organ damage and a higher mortality [10].
Conversely, and in accordance with the present findings,
the clinical course of late-onset SLE was described as
less aggressive [10]. It is also noteworthy that RP in
the elderly has different characteristics and pathogenic
mechanisms compared with younger individuals [11, 12].
As expected, more patients died in the older group.
Taken into account the international nature of the
EUSTAR database, mortality could not be compared with
an available age-matched control group. Unexpectedly, in
patients whose death was attributed to SSc, the median
survival time was longer in the older patients, furthermore
suggesting a more protracted course of SSc in the elderly.
Limitations of this study include missing information
concerning treatment modalities and co-medication, and
a possible bias related to differences in diagnostic
work-up and treatment of younger compared with older
patients. Inter-individual and centre bias might also
influence the results.
Taken together, limited disease and PH measured by
echocardiography are more prevalent in the elderly, but
these patients suffer less from digital ulcers.
SSc-unrelated left heart hypertrophy has to be considered
especially in late-onset SSc before the diagnosis of PH
can effectively be made and treatment started.
Rheumatology key messages
. Limited disease is more prevalent, yet digital ulcers
are less prevalent in late-onset SSc.
. PH in late-onset SSc is influenced by underlying
cardiovascular comorbidity.
. The time from diagnosis to death is longer in
late-onset SSc.
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